### **AMENDMENTS TO THE CLAIMS**

The following **Listing of Claims** will replace all prior versions, and listings of claims in the application.

- 1. (CURRENTLY AMENDED) A pharmaceutical composition comprising:
  - a pharmaceutically acceptable carrier, adjuvant or vehicle; and
  - a therapeutically effective amount of a compound having the structure:

$$\begin{array}{c}
R_{a} \\
R_{b}
\end{array}$$

$$\begin{array}{c}
Y_{1} \\
X_{1} \\
R_{5}
\end{array}$$

$$\begin{array}{c}
R_{1} \\
R_{5}
\end{array}$$

$$\begin{array}{c}
R_{4} \\
\end{array}$$

$$\begin{array}{c}
(I) \\
\end{array}$$

or pharmaceutically acceptable salt thereof;

wherein  $R_1$  and  $R_2$  are each independently hydrogen or lower alkyl;

R<sub>3</sub> is hydrogen or lower alkyl, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl moiety; or a prodrug moiety or an oxygen protecting group;

R<sub>4</sub> is hydrogen, halogen, -OR<sup>4A</sup>, oxo, -OC(=O)R<sup>4A</sup>, OCH<sub>3</sub> or -NR<sup>4A</sup>R<sup>4B</sup>; wherein R<sup>4A</sup> and R<sup>4B</sup> are independently hydrogen, lower alkyl or lower alkoxy; a nitrogen protecting group or an oxygen protecting group;

**R**<sub>5</sub> is hydrogen or lower alkyl;

 $\mathbf{R}_{6}$  is hydrogen or lower alkyl;

 $\mathbf{R}_a$  and each occurrence of  $\mathbf{R}_b$  and  $\mathbf{R}\mathbf{c}$  are independently hydrogen;

n is 3:

 $X_1$  is O, NR<sup>X1</sup> or CR<sup>X1</sup>R<sup>X2</sup>; wherein R<sup>X1</sup> and R<sup>X2</sup> are independently hydrogen;

**Q** is hydrogen, lower alkyl,

$$CH_3$$
  $CH_2$   $CH_3$   $CH_3$ 

 $Y_1$  and  $Y_2$  are independently hydrogen, lower alkyl, or  $CF_3$ ; or  $WR^{Y_1}$ ; wherein W is independently  $-O_7$ , or  $-NR^{Y_2}$ , wherein each occurrence of  $R^{Y_1}$  and  $R^{Y_2}$  is independently hydrogen, or lower alkyl; or an aliphatic, heteroaliphatic, or  $Y_1$  and  $Y_2$  together with the carbon

whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight,

with the proviso that the compound does not have the following structure:

- 2. **(ORIGINAL)** The composition of claim 1, wherein the dosage is between about 1 mg/kg to about 50 mg/kg of body weight.
- 3. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 0.1 mg/kg to about 40 mg/kg of body weight.

- 4. **(ORIGINAL)** The composition of claim 1, wherein the dosage is between about 1 mg/kg to about 40 mg/kg of body weight.
- 5. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 0.1 mg/kg to about 30 mg/kg of body weight.
- 6. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 5 mg/kg to about 30 mg/kg of body weight.
- 7. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 1 mg/kg to about 30 mg/kg of body weight.
- 8. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 0.1 mg/kg to about 20 mg/kg of body weight.
- 9. (ORIGINAL) The composition of claim 1, wherein the dosage is between about 1 mg/kg to about 20 mg/kg of body weight.
- 10. (ORIGINAL) The composition of claim 1, wherein the dosage is 10 mg/kg or greater of body weight.
- 11. (CURRENTLY AMENDED) The composition of claim 1, wherein:

 $\mathbf{R_1}$  and  $\mathbf{R_2}$  are each independently hydrogen or substituted or unsubstituted lower alkyl;  $\mathbf{R_3}$  is hydrogen, or substituted or unsubstituted lower alkyl;

$$\mathbf{R}_4$$
 is hydrogen, halogen,  $-\mathrm{OR}^{4\mathrm{A}}$ ,  $-\mathrm{OC}(=\mathrm{O})\mathrm{R}^{4\mathrm{A}}$ ,  $-\mathrm{oxo}$ ,  $-\mathrm{OC}(=\mathrm{O})\mathrm{R}^{4\mathrm{A}}$ , or or

-NR<sup>4A</sup>R<sup>4B</sup>; wherein R<sup>4A</sup> and R<sup>4B</sup> are independently hydrogen, or substituted or unsubstituted lower alkyl or lower alkoxy; a nitrogen protecting group or an oxygen protecting group;

 $\mathbf{R}_5$  and  $\mathbf{R}_6$  are each independently hydrogen or substituted or unsubstituted lower alkyl;  $\mathbf{R}_a$  and each occurrence of  $\mathbf{R}_b$  and  $\mathbf{R}\mathbf{c}$  are independently hydrogen;

**n** is 3:

 $X_1$  is O, NR<sup>X1</sup> or CR<sup>X1</sup>R<sup>X2</sup>; wherein R<sup>X1</sup> and R<sup>X2</sup> are independently hydrogen; Q is hydrogen, lower alkyl,

 $\mathbf{Y_1}$  and  $\mathbf{Y_2}$  are independently hydrogen, lower alkyl, or  $CF_3$ ; or  $WR^{Y1}$ ; wherein W is independently O, or  $NR^{Y2}$ , wherein each occurrence of  $R^{Y1}$  and  $R^{Y2}$  is independently hydrogen, or an alkyl, or  $\mathbf{Y_1}$  and  $\mathbf{Y_2}$  together with the carbon atom to which they are attached form a moiety

having the structure: 
$$(\sqrt{N})^{N} = \sqrt{N} \sqrt{N} + \sqrt{N} \sqrt{N} = \sqrt{N} \sqrt{N} + \sqrt{N} + \sqrt{N} \sqrt{N} + \sqrt{N} +$$

12. (CURRENTLY AMENDED) The composition of claim 1, wherein R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each hydrogen, and the compound has one of the following structures:

wherein  $R_1$ - $R_6$ ,  $Y_2$ ,  $X_1$ , n and Q are as defined in claim 1; W is O or NH; and  $R^{Y1}$  is hydrogen, or an aliphatic moiety, or or or heteroaliphatic moiety.

13. (CURRENTLY AMENDED) The composition of claim 1, wherein R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each hydrogen, Q is a carbonyl-containing moiety and the compound has one of the following structures:

wherein  $R_1$ - $R_6$ ,  $Y_2$ ,  $X_1$ , and n are as defined in claim 1; W is O or NH; and  $R^{Y1}$  is hydrogen, or an aliphatic, heteroaliphatic;  $R_7$  is a substituted or unsubstituted lower alkyl or heteroalkyl moiety;  $R_8$  is a substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl; and Alk is a substituted or unsubstituted  $C_{0-6}$  alkylenyl or  $\underline{\mathbf{a}}$   $C_{0-6}$  alkenylenyl chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, O,  $\underline{\mathbf{or}}$   $NR^{Z1}$ ,  $\underline{\mathbf{wherein}}$   $R^{Z1}$  is independently hydrogen or alkyl.

14. (CURRENTLY AMENDED) The composition of claim 1, wherein R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each hydrogen, n is 3 and the compound has one of the following structures:

wherein  $R_1$ - $R_6$ ,  $Y_2$ , Q and  $X_1$  are as defined in claim 1; W is O or NH; and  $R^{Y1}$  is hydrogen, or an aliphatic moiety, or a heteroaliphatic moiety.

15. **(CURRENTLY AMENDED)** The composition of claim 1, wherein R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each hydrogen, n is 3, Q is a carbonyl-containing moiety, and the compound has one of the following structures:

wherein  $R_1$ - $R_6$ ,  $X_1$  and  $Y_2$  are as defined in claim 1; W is O or NH;  $R^{Y1}$  is hydrogen, or an aliphatic <u>moiety</u>, or a heteroaliphatic <u>moiety</u>,  $R_7$  is a substituted or unsubstituted lower alkyl or heteroalkyl moiety;  $R_8$  is a substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl; and Alk is a substituted or unsubstituted  $C_{0-6}$  alkylenyl or  $C_{0-6}$  alkenylenyl chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, O,  $NR^{Z1}$ , wherein  $R^{Z1}$  is independently hydrogen, or alkyl, and  $R_8$  is a substituted or unsubstituted alkyl, heteroalkyl, eyeloalkyl, heterocycloalkyl.

- 16. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein  $R_1$  and  $R_2$  are each hydrogen.
- 17. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein R<sub>5</sub> and R<sub>6</sub> are each methyl.
- 18. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein R<sub>3</sub> is lower alkyl.
- 19. (ORIGINAL) The composition of claim 18, wherein  $R_3$  is methyl.
- 20. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein R<sub>4</sub> is OH, NH<sub>2</sub> or halogen.
- 21. (ORIGINAL) The composition of claim 13 or 15, wherein  $R_7$  is lower alkyl.
- 22. (ORIGINAL) The composition of claim 21, wherein  $R_7$  is methyl.

## 23. (CURRENTLY AMENDED) The composition of claim 1, wherein Q has the structure:

wherein  $R_7$  is a substituted or unsubstituted, <u>or a lower alkyl moiety</u>;  $R_8$  is a substituted or unsubstituted carbocyclic, or heterocyclic <u>moiety</u>; and X, Y and Z are independently a bond, -O-, -C(=O)-, -NR<sup>Z1</sup>-, -CHOR<sup>Z1</sup>, or a substituted or unsubstituted  $C_{0-6}$  alkylenyl or  $C_{0-6}$  alkenylenyl wherein up to two non-adjacent methylene units are independently optionally replaced by CO, O, or NR<sup>Z1</sup>and each occurrence of , wherein R<sup>Z1</sup> is hydrogen or alkyl; and pharmaceutically acceptable derivatives thereof.

## 24. (CURRENTLY AMENDED) The composition of claim 23, wherein Q has the structure:

wherein  $R_7$  is a substituted or unsubstituted lower alkyl moiety;  $R_8$  is a substituted or unsubstituted carbocyclic <u>moiety</u>, or <u>a</u> heterocyclic <u>moiety</u>; and  $R^Y$  is hydrogen, -OR<sup>Y1</sup>; wherein  $R^{Y1}$  is hydrogen, alkyl, or heteroalkyl.

### 25. (CURRENTLY AMENDED) The composition claim 13, wherein R<sub>8</sub> is one of:

wherein p is an integer from 0 to 5; q is 1 or 2, r is an integer from 1 to 6; each occurrence of  $R^{8A}$  is independently hydrogen, and each occurrence of  $R^{8B}$  is independently hydrogen or lower alkyl.

26. (ORIGINAL) The composition of claim 25, wherein  $R_8$  has the structure:

wherein R<sup>8B</sup> is hydrogen or lower alkyl.

- 27. (PREVIOUSLY PRESENTED) The composition of claim 1 wherein n is 3.
- 28. (PREVIOUSLY PRESENTED) The composition of claim 12 wherein  $Y_1$  is  $OR^{Y_1}$  and  $Y_2$  is lower alkyl; wherein  $R^{Y_1}$  is hydrogen or lower alkyl.
- 29. (ORIGINAL) The composition of claim 28, wherein  $Y_1$  is OH and  $Y_2$  is  $CF_3$ .
- 30. (ORIGINAL) The composition of claim 11 wherein R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each hydrogen, and the compound has one of the structures:

or pharmaceutically acceptable derivative thereof;

wherein  $R_3$ - $R_6$ , n and Q are as defined in claim 1; and  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl.

31. (ORIGINAL) The composition of claim 1 wherein the compound has the structure:

or pharmaceutically acceptable derivative thereof;

wherein  $R_3$ - $R_6$  and Q are as defined in claim 11; and  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl.

# 32. **(PREVIOUSLY PRESENTED)** The composition of claim 11 wherein the compound has the structure:

or pharmaceutically acceptable derivative thereof;

wherein  $R_3$ - $R_6$  and n are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted lower alkyl moiety;  $R^{8B}$  is hydrogen or lower alkyl; and X, Y and Z are independently a bond, -O-, -C(=O)-, -NR<sup>Z1</sup>-, -CHOR<sup>Z1</sup>; or a substituted or unsubstituted  $C_{0-6}$  alkylenyl or  $C_{0-6}$  alkenylenyl chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, O, or NR<sup>Z1</sup>; and  $R^{Z1}$  is hydrogen, or alkyl.

33. (PREVIOUSLY PRESENTED) The composition of claim 11 wherein the compound has the structure:

or pharmaceutically acceptable derivative thereof;

wherein  $R_3$ - $R_6$  are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted, lower alkyl moiety;  $R^{8B}$  is hydrogen or lower alkyl; and X, Y and Z are independently a bond, -O-, -C(=O)-, -NR<sup>Z1</sup>, or -CHOR<sup>Z1</sup>; or a substituted or unsubstituted  $C_{0-6}$  alkylenyl or  $C_{0-6}$  alkenylenyl chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, O, or NR<sup>Z1</sup>; and  $R^{Z1}$  is hydrogen or alkyl.

34. **(PREVIOUSLY PRESENTED)** The composition of claim 32 or 33, wherein –X-Y-Z together represents the moiety -CH<sub>2</sub>-Y-CH<sub>2</sub>; wherein Y is -CHOR<sup>Y1</sup> or C=O; and R<sup>Y1</sup> and R<sup>Y2</sup> are independently hydrogen or alkyl.

35. **(PREVIOUSLY PRESENTED)** The composition of claim 11 wherein the compound has the structure:

wherein  $R_3$ - $R_6$  and n are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted, lower alkyl moiety;  $R^{8B}$  is hydrogen or lower alkyl; and Y is -CHOR<sup>Y1</sup>, or C=O, and  $R^{Y1}$  is hydrogen, alkyl, or heteroalkyl.

wherein  $R_3$ - $R_6$  are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted, lower alkyl moiety;  $R^{8B}$  is hydrogen or lower alkyl; and Y is -CHOR<sup>Y1</sup>, or C=O; and  $R^{Y1}$  is hydrogen, alkyl, or heteroalkyl.

wherein n,  $R_3$  and  $R_4$  are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R^{8B}$  is hydrogen or lower alkyl; and  $R^Y$  is hydrogen, or  $-OR^{Y1}$ ; wherein  $R^{Y1}$  is hydrogen, alkyl, or heteroalkyl.

wherein  $R_3$  and  $R_4$  are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R^{8B}$  is hydrogen or lower alkyl; and  $R^Y$  is hydrogen, or  $-OR^{Y1}$ ; wherein  $R^{Y1}$  is hydrogen, alkyl, or heteroalkyl.

wherein  $R_3$ - $R_6$  and n are as defined in claim 11;  $Y_2$  and  $R^{YI}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted, lower alkyl moiety; and  $R^{8B}$  is hydrogen or lower alkyl.

wherein  $R_3$ - $R_6$  are as defined in claim 11;  $Y_2$  and  $R^{Y1}$  are independently hydrogen or lower alkyl;  $R_7$  is a substituted or unsubstituted, lower alkyl moiety; and  $R^{8B}$  is hydrogen or lower alkyl.

41. (CURRENTLY AMENDED) The composition of claim 11 wherein the compound has the following structure:

or a pharmaceutically acceptable salt thereof; wherein  $X_1$  is  $CH_2$ , NH or O;

 $Y_1$  and  $Y_2$  are independently OH,  $C(R^{Y1})_3$  or  $Y_1$  and  $Y_2$  taken together with the carbon atom to which they are attached are -C=0, wherein  $R^{Y1}$  is halo;

R<sub>6</sub> is H or lower alkyl;

R<sub>5</sub> is H or lower alkyl;

R<sub>4</sub> is OH, -OAc or oxo; and

R<sub>3</sub> is alkyl.

42. (ORIGINAL) The composition of claim 41 wherein the compound has one of the following structures:

Claims 43 and 44 (CANCELED).

- 45. (ORIGINAL) The composition of claim 1, further comprising a cytotoxic agent.
- 46. (ORIGINAL) The composition of claim 45, wherein the cytotoxic agent is an anticancer agent.
- 47. (ORIGINAL) The composition of claim 1, further comprising a palliative agent.

Claims 48-62 (CANCELED).